Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston Sep 2, 2021
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021 Jul 21, 2021
Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements Jul 12, 2021
Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021 Jun 25, 2021
Poxel Announces Results from June 23, 2021 Ordinary Annual and Extraordinary General Meeting Jun 24, 2021
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan Jun 23, 2021
Poxel Announces Participation and Presentations at the EASL (European Association for the Study of the Liver) International Liver CongressTM 2021 Jun 21, 2021
Poxel Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS) May 20, 2021
